SCHEMBL1008743

SCHEMBL1008743

N#Cc1ncccc1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
ERBB2 P04626 1/20 0.43
LRRK2 Q5S007 2/20 0.41
CLK4 Q9HAZ1 2/20 0.40
TOP1 P11387 1/20 0.40
CHEK1 O14757 1/20 0.40
ABL1 P00519 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT1 P17948 1/20 0.40
GRK5 P34947 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28024938 0.86 PRMT5 (0.42) CYP2C19PRMT5WDR77CDK8PTGS1
SCHEMBL18421684 0.85 PRMT5 (0.41) ALOX15ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL17116599 0.85 PRMT5 (0.47) PRMT5WDR77CLK4GSK3BGRM5
SCHEMBL17116282 0.84 PRMT5 (0.43) ALOX15ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL18462115 0.84 PRMT5 (0.44) ALOX15ALDH1A1PRMT5WDR77LRRK2
SCHEMBL14735824 0.83 CYP11B2 (0.51) ALOX15ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3711809 0.83 KDM4E (0.45) ALDH1A1MEN1KMT2ACYP1A2PRMT5
SCHEMBL17116724 0.83 PRMT5 (0.43) ALOX15PRMT5WDR77CLK4GSK3B
SCHEMBL22290166 0.83 ERBB2 (0.45) ALDH1A1MEN1KMT2APRMT5WDR77
SCHEMBL17117023 0.83 PRMT5 (0.46) ALOX15ALDH1A1PRMT5WDR77CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431259-A Electron transport layer material and preparation method and application thereof 吉林奥来德光电材料股份有限公司 2025-02-14 CN disclosed
CN-116199699-A Organic compound and application thereof 奥来德(上海)光电材料科技有限公司 2023-06-02 CN disclosed
CN-112479986-A Method for selective mono-diene alkylation reaction of aromatic compound based on activation of hydrocarbon and pyridine as guide group 四川大学 2021-03-12 CN disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC ALOX15 1495/4885ALDH1A1 287/4885MEN1 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.